LU92943I2 - Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa) - Google Patents

Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa) Download PDF

Info

Publication number: LU92943I2
Authority: LU; Luxembourg
Prior art keywords: salt; zerbaxa; ceftolozane; pharmaceutically acceptable; sulfuric acid
Prior art date: 2002-10-30

Application number

LU92943C

Other languages

English (en)

Original Assignee

Astellas Pharma Inc

Wakunaga Pharma Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-10-30

Filing date

2016-01-12

Publication date

2016-03-14

2002-10-30 Priority claimed from AU2002952355A external-priority patent/AU2002952355A0/en

2003-09-04 Priority claimed from AU2003904813A external-priority patent/AU2003904813A0/en

2016-01-12 Application filed by Astellas Pharma Inc, Wakunaga Pharma Co Ltd filed Critical Astellas Pharma Inc

2016-03-14 Publication of LU92943I2 publication Critical patent/LU92943I2/fr

Links

QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 title 2
150000003839 salts Chemical class 0.000 title 2
GRHWKSLBMDQBQW-KZVOOCJBSA-N (6r,7r)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-7-[[(2e)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(2-carboxypropan-2-yloxyimino)acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;(2s,3s)-3-methyl-4,4,7-t Chemical compound C([C@]1(C)S(C2N(C(C2)=O)[C@H]1C(O)=O)(=O)=O)N1C=CN=N1.CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C([O-])=O)N2C(=O)[C@@H](NC(=O)C(=N\OC(C)(C)C(O)=O)\C=3N=C(N)SN=3)[C@H]2SC1 GRHWKSLBMDQBQW-KZVOOCJBSA-N 0.000 title 1
UJDQGRLTPBVSFN-TVNHLQOTSA-N 2-[(z)-[2-[[(6r,7r)-3-[[3-amino-4-(2-aminoethylcarbamoylamino)-2-methylpyrazol-1-ium-1-yl]methyl]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-7-yl]amino]-1-(5-amino-1,2,4-thiadiazol-3-yl)-2-oxoethylidene]amino]oxy-2-methylpropanoate;sulfuric acid Chemical compound OS(O)(=O)=O.CN1C(N)=C(NC(=O)NCCN)C=[N+]1CC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)C(=N/OC(C)(C)C([O-])=O)\C=3N=C(N)SN=3)[C@H]2SC1 UJDQGRLTPBVSFN-TVNHLQOTSA-N 0.000 title 1
229960002405 ceftolozane Drugs 0.000 title 1
229940099705 zerbaxa Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
- C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cephalosporin Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

LU92943C 2002-10-30 2016-01-12 Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa) LU92943I2 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AU2002952355A AU2002952355A0 (en)	2002-10-30	2002-10-30	Cephem compounds
AU2003904813A AU2003904813A0 (en)		2003-09-04	Cephem Compounds
PCT/JP2003/013684 WO2004039814A1 (fr)	2002-10-30	2003-10-27	Composes cepheme

Publications (1)

Publication Number	Publication Date
LU92943I2 true LU92943I2 (fr)	2016-03-14

Family

ID=32231625

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LU92943C LU92943I2 (fr)	2002-10-30	2016-01-12	Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)

Country Status (19)

Country	Link
US (2)	US7129232B2 (fr)
EP (1)	EP1556389B9 (fr)
JP (1)	JP4448821B2 (fr)
KR (1)	KR101023035B1 (fr)
AR (1)	AR041729A1 (fr)
AT (1)	ATE368042T1 (fr)
BE (1)	BE2016C002I2 (fr)
BR (1)	BRPI0315188B8 (fr)
CA (1)	CA2504730C (fr)
DE (1)	DE60315178T3 (fr)
DK (1)	DK1556389T6 (fr)
ES (1)	ES2290498T7 (fr)
FR (1)	FR16C0004I2 (fr)
HU (1)	HUS1600008I1 (fr)
LU (1)	LU92943I2 (fr)
NL (1)	NL300793I1 (fr)
PT (1)	PT1556389E (fr)
TW (1)	TWI319403B (fr)
WO (1)	WO2004039814A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4251873B2 (ja) *	2001-05-01	2009-04-08	アステラス製薬株式会社	セフェム化合物
BRPI0315188B8 (pt) *	2002-10-30	2021-05-25	Astellas Pharma Inc	composto e composição farmacêutica
AU2003902380A0 (en) *	2003-05-16	2003-06-05	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds
JP4643577B2 (ja) *	2003-09-18	2011-03-02	アステラス製薬株式会社	セフェム化合物
EP2308562B1 (fr) *	2003-12-25	2015-02-25	Ono Pharmaceutical Co., Ltd.	Composes cycliques d'azetidine et medicaments les renfermant
JP2009530228A (ja) *	2006-03-16	2009-08-27	アステラス製薬株式会社	セフェム化合物および抗菌薬としての利用
ITFE20060029A1 (it) *	2006-10-17	2008-04-18	Gruppo Kemon Spa	Intermedi eterociclici primari per la colorazione ossidativa dei capelli a struttura pirazolica
CA2935651A1 (fr)	2007-10-09	2009-04-16	Gladius Pharmaceuticals Corporation	Inhibiteurs de beta-lactamase a large spectre
MY173181A (en)	2011-05-13	2020-01-02	Array Biopharma Inc	Pyrrolidinyl urea, pyrrolidinyl thiourea and pyrrolidinyl guanidine compounds as trka kinase inhibitors
SI3616695T1 (sl)	2011-09-09	2025-01-31	Merck Sharp & Dohme Llc	Ceftolozan/tazobaktam za zdravljenje intrapulmonalnih okužb
EP2628730B1 (fr) *	2012-02-16	2017-12-06	Noxell Corporation	Synthèse télescopique des sels de 5-amino-4-nitroso-1-alkyl-1h-pyrazole
US8809314B1 (en)	2012-09-07	2014-08-19	Cubist Pharmacueticals, Inc.	Cephalosporin compound
WO2014052799A1 (fr)	2012-09-27	2014-04-03	Cubist Pharmaceuticals, Inc.	Compositions antibiotiques à base d'arginine-tazobactame
US8476425B1 (en)	2012-09-27	2013-07-02	Cubist Pharmaceuticals, Inc.	Tazobactam arginine compositions
US20140274999A1 (en)	2013-03-14	2014-09-18	Cubist Pharmaceuticals, Inc.	Cephalosporin compositions and methods of manufacture
US9872906B2 (en)	2013-03-15	2018-01-23	Merck Sharp & Dohme Corp.	Ceftolozane antibiotic compositions
UA121298C2 (uk) *	2013-03-15	2020-05-12	Мерк Шарп І Доум Корп.	Антибіотична композиція на основі цефтолозану і тазобактаму
US20140274997A1 (en)	2013-03-15	2014-09-18	Cubist Pharmaceuticals, Inc.	Cephalosporin pharmaceutical compositions
AU2014233637A1 (en)	2013-09-09	2015-03-26	Merck Sharp & Dohme Corp.	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20160228448A1 (en) *	2013-09-27	2016-08-11	Merck Sharp & Dohme Corp.	Solid Forms of Ceftolozane
US20150094293A1 (en)	2013-09-27	2015-04-02	Calixa Therapeutics, Inc.	Solid forms of ceftolozane
US9120796B2 (en)	2013-10-02	2015-09-01	Cubist Pharmaceuticals, Inc.	B-lactamase inhibitor picoline salt
LT3154959T (lt)	2014-05-15	2019-09-25	Array Biopharma, Inc.	1-((3s,4r)-4-(3-fluorfenil)-1-(2-metoksietil)pirolidin-3-il)-3-(4-metil-3-(2-metilpirimidin-5-il)-1-fenil-1h-pirazol-5-il)karbamidas kaip trka kinazės inhibitorius
CN106795175A (zh)	2014-08-15	2017-05-31	默沙东公司	头孢菌素化合物的合成
US10221196B2 (en)	2014-08-15	2019-03-05	Merck Sharp & Dohme Corp.	Intermediates in the synthesis of cephalosporin compounds
WO2016028670A1 (fr) *	2014-08-18	2016-02-25	Merck Sharp & Dohme Corp.	Formes salines de ceftolozane
WO2016100897A1 (fr) *	2014-12-18	2016-06-23	Merck Sharp & Dohme Corp.	Composés dérivés de l'acide thiadiazolyl-oxyminoacétique
WO2016095860A1 (fr) *	2014-12-18	2016-06-23	Merck Sharp & Dohme Corp.	Composés sous forme de dérivés d'acide pyrazolyl-carboxylique et de pyrazolyl-urée
US20160176897A1 (en)	2014-12-23	2016-06-23	Merck Sharp & Dohme Corp.	7-aminocephem derivative compounds
US10214543B2 (en)	2014-12-30	2019-02-26	Merck Sharp & Dohme Corp.	Synthesis of cephalosporin compounds
ES2729026T3 (es) *	2015-06-29	2019-10-29	Sandoz Ag	Procedimiento para la preparación de derivados de carbamoilamino pirazol
CN107922435B (zh)	2015-09-08	2022-05-17	桑多斯股份公司	由7-氨基头孢烷酸(7-aca)制备头孢洛扎的方法
KR20180066264A (ko)	2015-12-10	2018-06-18	나에자-알지엠 파마슈티칼스 유엘씨	세펨 화합물, 그의 제조 및 용도
CN109195967A (zh)	2016-06-06	2019-01-11	默沙东公司	头孢洛扎的固体形式和制备方法
CN107586305A (zh) *	2017-06-23	2018-01-16	浙江惠迪森药业有限公司	一种β‑内酰胺类化合物羧基及羟基保护基脱除方法
WO2019145784A2 (fr) *	2018-01-26	2019-08-01	Legochem Biosciences, Inc.	Polythérapies pour agents pathogènes résistant aux médicaments multiples
CN109369535A (zh) *	2018-11-07	2019-02-22	浙江东邦药业有限公司	一种氨基甲酰氨基吡唑衍生化合物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GR78245B (fr) *	1980-09-12	1984-09-26	Ciba Geigy Ag
US5194432A (en)	1985-11-22	1993-03-16	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds
CA1293719C (fr) *	1986-09-22	1991-12-31	Takao Takaya	Composes de cephem et procede de preparation
US5210080A (en) *	1987-09-07	1993-05-11	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds
US5663163A (en) *	1987-09-07	1997-09-02	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds and processes for preparation thereof
IE63094B1 (en) *	1987-09-14	1995-03-22	Fujisawa Pharmaceutical Co	Cephem compound and a process for preparation thereof
US5173485A (en) *	1988-03-09	1992-12-22	Fujisawa Pharmaceutical Company, Ltd.	Cephem compounds
GB8905301D0 (en) *	1989-03-08	1989-04-19	Fujisawa Pharmaceutical Co	New cephem compound and a process for preparation thereof
US5215982A (en) *	1989-11-10	1993-06-01	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds
KR910015587A (ko) *	1990-02-27	1991-09-30	후지사와 토모키치로	세펨 화합물
GB9023479D0 (en) *	1990-10-29	1990-12-12	Fujisawa Pharmaceutical Co	New cephem compounds and processes for preparation thereof
JPH09110877A (ja)	1995-10-17	1997-04-28	Katayama Seiyakushiyo:Kk	セフェム化合物、その製造法及びそれを含有する抗菌剤
AUPN955596A0 (en)	1996-04-30	1996-05-23	Fujisawa Pharmaceutical Co., Ltd.	New compound
TW526202B (en) *	1998-11-27	2003-04-01	Shionogi & Amp Co	Broad spectrum cephem having benzo[4,5-b]pyridium methyl group of antibiotic activity
JP4251873B2 (ja) *	2001-05-01	2009-04-08	アステラス製薬株式会社	セフェム化合物
BRPI0315188B8 (pt) *	2002-10-30	2021-05-25	Astellas Pharma Inc	composto e composição farmacêutica
AU2003902380A0 (en) *	2003-05-16	2003-06-05	Fujisawa Pharmaceutical Co., Ltd.	Cephem compounds
JP4643577B2 (ja) *	2003-09-18	2011-03-02	アステラス製薬株式会社	セフェム化合物

2003
- 2003-10-27 BR BRPI0315188A patent/BRPI0315188B8/pt not_active IP Right Cessation
- 2003-10-27 EP EP03758919.9A patent/EP1556389B9/fr not_active Expired - Lifetime
- 2003-10-27 KR KR1020057007538A patent/KR101023035B1/ko not_active Expired - Lifetime
- 2003-10-27 ES ES03758919.9T patent/ES2290498T7/es active Active
- 2003-10-27 AT AT03758919T patent/ATE368042T1/de active
- 2003-10-27 DE DE60315178.7T patent/DE60315178T3/de not_active Expired - Lifetime
- 2003-10-27 PT PT03758919T patent/PT1556389E/pt unknown
- 2003-10-27 WO PCT/JP2003/013684 patent/WO2004039814A1/fr not_active Ceased
- 2003-10-27 DK DK03758919.9T patent/DK1556389T6/da active
- 2003-10-27 CA CA2504730A patent/CA2504730C/fr not_active Expired - Lifetime
- 2003-10-27 JP JP2005501847A patent/JP4448821B2/ja not_active Expired - Lifetime
- 2003-10-29 TW TW092129984A patent/TWI319403B/zh active
- 2003-10-30 US US10/695,895 patent/US7129232B2/en active Active
- 2003-10-30 AR ARP030103985A patent/AR041729A1/es active IP Right Grant
2006
- 2006-10-24 US US11/585,262 patent/US20070037786A1/en not_active Abandoned
2016
- 2016-01-12 LU LU92943C patent/LU92943I2/fr unknown
- 2016-01-21 BE BE2016C002C patent/BE2016C002I2/fr unknown
- 2016-01-28 HU HUS1600008C patent/HUS1600008I1/hu unknown
- 2016-02-03 FR FR16C0004C patent/FR16C0004I2/fr active Active
- 2016-02-04 NL NL300793C patent/NL300793I1/nl unknown

Also Published As

Publication number	Publication date
ES2290498T7 (es)	2015-07-10
JP2006506459A (ja)	2006-02-23
EP1556389B3 (fr)	2015-04-01
ATE368042T1 (de)	2007-08-15
KR20050084897A (ko)	2005-08-29
DE60315178D1 (de)	2007-09-06
JP4448821B2 (ja)	2010-04-14
BR0315188A (pt)	2005-09-06
KR101023035B1 (ko)	2011-03-24
ES2290498T3 (es)	2008-02-16
US7129232B2 (en)	2006-10-31
EP1556389B1 (fr)	2007-07-25
HK1086566A1 (zh)	2006-09-22
EP1556389B9 (fr)	2015-09-09
TW200410977A (en)	2004-07-01
BE2016C002I2 (fr)	2023-03-07
DK1556389T6 (da)	2015-05-11
FR16C0004I2 (fr)	2017-01-06
TWI319403B (en)	2010-01-11
BRPI0315188B8 (pt)	2021-05-25
CA2504730C (fr)	2011-04-12
NL300793I2 (fr)	2016-03-15
WO2004039814A1 (fr)	2004-05-13
CA2504730A1 (fr)	2004-05-13
AR041729A1 (es)	2005-05-26
US20070037786A1 (en)	2007-02-15
HUS1600008I1 (hu)	2016-03-29
DK1556389T3 (da)	2007-11-26
EP1556389A1 (fr)	2005-07-27
DE60315178T2 (de)	2008-04-30
BRPI0315188B1 (pt)	2017-04-25
NL300793I1 (fr)	2016-03-15
US20040132994A1 (en)	2004-07-08
DE60315178T3 (de)	2015-06-18
FR16C0004I1 (fr)	2016-03-25
PT1556389E (pt)	2007-11-08

Publication	Publication Date	Title
LU92943I2 (fr)	2016-03-14	Ceftolozane ou un sel pharmaceutiquement acceptable, en particulier un sel d'acide sulfurique (zerbaxa)
LU92397I2 (fr)	2014-05-12	Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable
LU92520I2 (fr)	2015-11-02	Bédaquiline, ou son sel d'addition d'acide ou de base pharmaceutiquement acceptable, y compris le fumarate de bédaquiline
LU91534I2 (fr)	2009-04-27	"Acide nicotinique/laropiprant"
EP1569943A4 (fr)	2007-11-28	Procede pour la preparation de chelate d'acide amine
FR2848390B1 (fr)	2005-07-08	Article chaussant notamment pour l'escalade
DE60117289D1 (de)	2006-04-20	Schnelllösliche tabletten
ZA200300196B (en)	2003-11-05	Substituted sulfonyl aminomethyl benzoic acid (derivatives) and method for the production thereof.
IL159547A0 (en)	2004-06-01	Novel vinyl carboxylic acid derivatives and their use as antidiabetics
MA27033A1 (fr)	2004-12-20	Derives d'acides sulfoniques nouveaux
PL373624A1 (en)	2005-09-05	4-[7-halo-2-quino (xa-) linyloxy]phenoxy-propionic acid derivatives as antineoplastic agents
GB2378978B (en)	2003-07-23	Builder's trestles
EP1484406A4 (fr)	2005-07-27	Procede de fabrication d'acide n-acetylneuraminique
PL376926A1 (pl)	2006-01-09	Nowe analogi 2',5'-oligoadenylanowe
ATE369342T1 (de)	2007-08-15	2,5-disubstituierte 3-mercaptopentansaure
ITMI20011132A1 (it)	2002-11-29	Procedimento per la preparazione dell'acido 1-amminometil-1-cicloesanacetico
PL366980A1 (en)	2005-02-07	Hydroxyeicosenoic acid analogs
ITTO20020102A1 (it)	2003-08-06	Procedimento per la preparazione dell'acido ursodesossicolico disolfato e suoi sali farmaceuticamente accettabili.
AU151083S (en)	2003-03-18	Swimmer's starting block
ITMI20011718A0 (it)	2001-08-03	Processo per la preparazione del sale sodico dell'acido-6(d-(-)-alpha-(4-etil-2,3-diosso-1-piperazinocarbonilammino)fenilacetammido)penicill
ITMI20030822A1 (it)	2004-10-19	Processo per la preparazione dell'acido ursodesossicolico
EP1570049A4 (fr)	2006-05-10	Micro-organisme produisant l'acide 5'-xanthylique
FR2847481B1 (fr)	2007-01-05	Mousqueton double pour l'escalade
ITMI20031471A1 (it)	2005-01-19	Processo per la racemizzazione dell'acido etodolico
ITMI20021168A1 (it)	2003-12-01	Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico